Tumor eradication by immunotherapy with biodegradable PLGA microspheres-an alternative to incomplete Freund's adjuvant

International Journal of Cancer

Volumn 129, Issue 2, 2011, Pages 407-416

  Mueller, Marc ^a   Schlosser, Eva ^a   Gander, Bruno ^b   Groettrup, Marcus ^a,c  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF KONSTANZ   (Switzerland)

Author keywords

Cancer; In vivo cytotoxicity; Incomplete Freund's adjuvant; Microspheres; Stimulation of T cell proliferation

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MICROSPHERE; OVALBUMIN; POLYGLACTIN; TUMOR NECROSIS FACTOR ALPHA; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; INCOMPLETE FREUND'S ADJUVANT; LACTIC ACID; LIPID; OLIGODEOXYRIBONUCLEOTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EX VIVO STUDY; HUMORAL IMMUNITY; IN VIVO STUDY; INTERFERON PRODUCTION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TH1 CELL; THYMOMA; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; IMMUNOTHERAPY; LACTIC ACID; LIPIDS; MELANOMA; MICE; MICE, INBRED C57BL; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; POLYGLYCOLIC ACID; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 79961112408     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25914     Document Type: Article

References (49)

1. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-87. (Pubitemid 20059033)
2. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006;440:808-12.
3. Yarovinsky F, Kanzler H, Hieny S, Coffman RL, Sher A. Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 2006;25:655-64. (Pubitemid 44529033)
4. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization: A review. Am J Clin Pathol 1951;21:645-56.
5. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligonucleotide 7909. J Clin Invest 2005; 115:739-46. (Pubitemid 40322250)
6. Moss RB, Diveley J, Jensen F, Carlo DJ. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine 2000;18: 1081-7.
7. Toledo H, Baly A, Castro O, Resik S, Laferte J, Rolo F, Navea L, Lobaina L, Cruz O, Miguez J, Serrano T, Sierra B, et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001; 19:4328-36. (Pubitemid 32703655)
8. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.
9. WaeckerleMen Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005;57:475-82. (Pubitemid 39550972)
10. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Petrilli V, Tschopp J, O'Neill LA, Lavelle EC. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009;106:870-5.
11. Malyala P, O'Hagan DT, Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 2009; 61:218-25.
12. Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007;28:3427-36. (Pubitemid 46729729)
13. Guillon C, Mayol K, Terrat C, Compagnon C, Primard C, Charles MH, Delair T, Munier S, Verrier B. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 2007;25: 7491-501. (Pubitemid 47516619)
14. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000; 50:129-46. (Pubitemid 30326693)
15. Waeckerle-Men Y, Gander B, Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005;109:35-46.
16. Waeckerle-Men Y, Scandella E, Allmen EU, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M. Phenotype and functional analysis of human monocytederived dendritic cells loaded with biodegradable poly(lactide-co- glycolide) microspheres for immunotherapy. J Immunol Method 2004;287:109-24. (Pubitemid 38510213)
17. Waeckerle-Men Y, UetzvonAllmen E, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HR, Groettrup M. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006;24:1847-57. (Pubitemid 43238266)
18. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008;26: 1626-37.
19. Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvans efficiently drive protective T cell immunity. Eur J Immunol 2007;37: 2063-74. (Pubitemid 47250198)
20. Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007; 81:652-62. (Pubitemid 46786896)
21. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Co-delivery of cancerassociated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008;26:5046-57.
22. Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD. Immune stimulatory antigen loaded particles combined with depletion of regulatory Tcells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 2009;58: 517-30.
23. San Roman B, Irache JM, Gomez S, Tsapis N, Gamazo C, Espuelas MS. Coencapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008;70:98-108.
24. Restifo NP, Bacik I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 1995; 154:4414-22.
25. Gorer PA, Kaliss N. The effect of isoantibodies in vivo on three different transplantable neoplasms in mice. Cancer Res 1959;19:824-30.
26. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway on antigen processing and presentation. Cell 1988;54:777-85.
27. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30. (Pubitemid 27355467)
28. Barber DL, Wherry EJ, Ahmed R. Cutting edge: Rapid in vivo killing by memory CD8 T cells. J Immunol 2003;171:27-31. (Pubitemid 36745269)
29. Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1 but not PA28a/b enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol 2000;165:768-78. (Pubitemid 30484743)
30. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 1996;193: 199-206. (Pubitemid 26227987)
31. Martin-Fonteccha A, Sebastiani S, Höpken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F. Regulation of dendritic cell migration to the drining lymph node: Impact on T lymphocyte traffic and priming. J Exp Med 2003;198: 615-21. (Pubitemid 37040395)
32. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nat Med 1996;2: 52-8. (Pubitemid 26028073)
33. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells. Nat Med 1998;4: 328-32. (Pubitemid 28144092)
34. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G. Rapid induction of tumorspecific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88. (Pubitemid 34564330)
35. Schuler G, SchulerThurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47. (Pubitemid 36287518)
36. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Boehme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cellbased multi-epitope immuntherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006;55: 1524-33. (Pubitemid 44327840)
37. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008;26:3209-22.
38. Brewer JM. (How) do aluminium adjuvants work?Immunol Lett 2006;102: 10-15.
39. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008;26:552-61.
40. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995;6:277-96.
41. Casella CR, Mitchell TC. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008;65:3231-40.
42. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003;2: 219-29. (Pubitemid 36559927)
43. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR. Three doubleblind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001;19:3957-67. (Pubitemid 32566320)
44. Ballou WR. The development of the RTS,S malaria vaccine candidate: Challenges and lessons. Parasite Immunol 2009;31: 492-500.
45. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183: 6186-97.
46. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24: 5937-49. (Pubitemid 44080367)
47. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87. (Pubitemid 351377994)
48. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009; 125:2104-13.
49. Men Y, Gander B, Merkle HP, Corradin G. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 1996;14:1442-50. (Pubitemid 27008260)